Molecular Diagnostics News and Research

RSS

Fast Forward, Lineagen to fund clinical development and validation of blood-based assay for MS

Lineagen, Inc., an innovative molecular diagnostics company focused on complex, genetically linked disorders, and Fast Forward, LLC, a nonprofit subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the clinical development and validation of a blood-based assay for multiple sclerosis.

15 Dec 2011

Recommendations to address challenges associated with chronic inflammatory diseases

A dramatic increase in the incidence of chronic inflammatory diseases such as asthma, allergy, and irritable bowel syndrome, has led to concern about how modern lifestyles may trigger physiological defense mechanisms.

8 Dec 2011

GE Healthcare invests in C8 MediSensors to focus on disease management solutions

GE Capital and GE Healthcare, the financial services and healthcare divisions of General Electric Company, announced today an investment in C8 MediSensors, Inc., a privately held developer of non-invasive continuous glucose monitors for diabetic patients.

2 Dec 2011

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

29 Nov 2011

Roche establishes strategic alliance with Cedars-Sinai Medical Center

Roche announced today the establishment of a strategic alliance with Cedars-Sinai Medical Center in Los Angeles for the center to operate as a Roche Molecular Center of Excellence (MCOE) for the next five years.

From Roche Sequencing and Life Science 21 Nov 2011

AMP announces Council's unanimous approval of strategic plan for personalized medicine

The Association for Molecular Pathology (AMP) today announced the AMP Council's unanimous approval of a strategic plan intended to guide the organization over the next four years.

19 Nov 2011

MDxHealth total revenues decrease 7% for third quarter 2011

MDxHealth SA, a leading molecular diagnostics company in the field of personalized medicine, today issued its business update for the third quarter and for the nine months ended September 30, 2011.

17 Nov 2011

CF Foundation, Genzyme announce new drug research agreement

Genzyme, a Sanofi company, and Cystic Fibrosis Foundation Therapeutics Inc., the nonprofit affiliate of the Cystic Fibrosis Foundation, today announced a research agreement to support the discovery of new drugs to treat people with the most common mutation found in patients with CF, Delta F508.

17 Nov 2011

Positive data from MDxHealth's prostate cancer test study

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced data showing that a prototype of its Prostate ConfirmMDx test can help urologists distinguish patients who have a true negative biopsy from those who may have occult cancer undetected by prostate biopsy and histopathological review.

15 Nov 2011

Highmark now covers AlloMap for monitoring heart transplant rejection

XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive diagnostic tests to monitor immune-mediated conditions, today announced that Highmark Inc., an independent licensee of the Blue Cross Blue Shield Association, is now covering AlloMap for its beneficiaries.

9 Nov 2011

NanoString closes $20M Series D round of equity financing

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it has closed $20 million in a Series D round of equity financing.

From NanoString Technologies 7 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

Asuragen introduces ARQ IS Calibrator Panels to improve BCR-ABL1 testing for CML

Asuragen, Inc. announced today that it has commercially launched the ARQ IS Calibrator Panels (RUO), intended to aid laboratories with standardization of BCR-ABL1 quantitative measurements on the International Scale.

31 Oct 2011

DNA synbodies, a new class of affinity reagents, gets major NIH boost

An ongoing Arizona State University effort to develop a revolutionary class of reagents that holds great promise for the future of medicine has received a major boost with a three-year, $4 million award from the National Institutes of Health.

24 Oct 2011

NanoString introduces nCounter Analysis System

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the launch of its second generation nCounter Analysis System.

From NanoString Technologies 13 Oct 2011

New robust technique holds promise for identifying trace mutant DNA sequences

Molecular DNA testing methods offer clinicians powerful tools that serve to confirm or identify disease diagnoses. High sensitivity and high specificity, however, are frequently a challenge to achieve with these methods. In a study scheduled for publication in the November issue of The Journal of Molecular Diagnostics, researchers describe a new, robust technique that holds promise for identifying trace mutant DNA sequences in an overwhelming population of unmutated DNA.

12 Oct 2011

Virtual 18F-FDG PET/CT bronchoscopy may accurately detect NSCLC metastases

For patients with non-small cell lung cancer (NSCLC) the accurate determination of the lymph node status before therapy is critical to develop an individualized treatment plan. Research from the October issue of the Journal of Nuclear Medicine highlights a new way for this information to be collected -- a virtual fly-through three-dimensional 18F-FDG PET/computed tomography (FDG-PET/CT) bronchoscopy that has high diagnostic accuracy for the detection of regional lymph node metastases.

4 Oct 2011

Quidel, Life Technologies to distribute and commercialize molecular diagnostics in Europe

Life Technologies Corporation today announced that the company has signed an agreement with Quidel Corporation to distribute and commercialize molecular diagnostic assays for the European market.

22 Sep 2011

OPTOS to acquire ophthalmic instrumentation business from OPKO

OPKO Health, Inc. has agreed to sell its ophthalmic instrumentation business to OPTOS, Inc., a subsidiary of Optos plc, a leading and rapidly growing medical technology company engaged in the design, development, manufacture and marketing of devices to image the retina of the eye. Optos will pay OPKO $17.5 million in cash at closing, plus future royalties.